Oxytetracycline Tablets

Tetracycline antibiotics. This product is a broad-spectrum antibacterial agent. Many Rickettsia, Mycoplasma, Chlamydia, and Spirochete are sensitive to this product. Enterococci are resistant to it. Others such as Actinomycetes, Bacillus anthracis, Listeria monocytogenes, Clostridium, Nocardia, Vibrio, Brucella, Campylobacter, Yersinia, etc. are also sensitive to this product. Due to the widespread use of oxytetracycline and tetracyclines over the years, common clinical pathogens have serious resistance to oxytetracycline, including Gram-positive bacteria such as Staphylococcus and most Gram-negative bacteria. There is cross-resistance between this product and different varieties of tetracycline antibiotics. The mechanism of action of this product is that the drug can specifically bind to the A position of the 30S subunit of the bacterial ribosome, inhibit the growth of the peptide chain and affect the synthesis of bacterial proteins.

The main component of this product is oxytetracycline, its chemical name: 6-methyl-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide. Molecular formula: C22H24N2O9 Molecular weight: 460.44

This product is light yellow tablet or sugar-coated tablet.

1. This product can be used as a drug of choice for the following diseases: (1) Rickettsial diseases, including epidemic typhus, endemic typhus, Rocky Mountain fever, scrub typhus and Q fever. (2) Mycoplasma infections. (3) Chlamydia infections, including psittacosis, venereal disease, lymphoedema, nonspecific urethritis, salpingitis, cervicitis and trachoma. (4) Relapsing fever. (5) Brucellosis. (6) Cholera. (7) Tularemia.

Oral administration: 1.5-2g per day for adults, divided into 3-4 times; 30-40mg/kg per day for children over 8 years old, divided into 3-4 times. This product is contraindicated for children under 8 years old.

1. Digestive system: Gastrointestinal symptoms such as nausea, vomiting, upper abdominal discomfort, abdominal distension, diarrhea, and occasional reports of pancreatitis, esophagitis, and esophageal ulcers, mostly occur in patients who are bedridden immediately after taking the drug. 2. Hepatotoxicity: Usually fatty liver degeneration, pregnant women, and patients with pre-existing renal impairment are prone to hepatotoxicity, but hepatotoxicity can also occur in patients without the above conditions. 3. Allergic reactions: Mostly maculopapular rash and erythema, in addition to urticaria, angioneurotic edema, allergic purpura, pericarditis, and exacerbation of systemic lupus erythematosus, epidermal exfoliative dermatitis is not common. Occasionally, anaphylactic shock and asthma occur. Some patients using tetracycline have photosensitivity when exposed to the sun. Therefore, patients should be advised not to be directly exposed to sunlight or ultraviolet rays, and to stop taking the drug immediately if erythema appears on the skin.

Patients with a history of allergy to tetracyclines are contraindicated.

Precautions for children: This product can form stable calcium compounds in any bone tissue, leading to yellowing of permanent teeth, poor enamel development and bone growth inhibition, so it is not suitable for children under 8 years old. Precautions for pregnancy and lactation: This product can enter the fetus through the placental barrier and deposit in the calcium area of teeth and bones, causing fetal tooth discoloration, poor enamel regeneration and inhibition of fetal bone growth. In addition, this type of drug has teratogenic effects in animal experiments, so pregnant women should not use this product. This product can be secreted from breast milk, and the concentration in breast milk is high. It has the potential to cause serious adverse reactions to infants. Lactating women should suspend breastfeeding when using it. Precautions for the elderly: Elderly patients are often accompanied by renal impairment. The use of this product is prone to hepatotoxicity. Therefore, when elderly patients use this product, the dosage should be adjusted according to the degree of renal impairment.

1. When used with antacids such as sodium bicarbonate, the absorption of this product will be reduced and its activity will be reduced due to the increase in the pH value in the stomach. Therefore, antacids should not be taken within 1 to 3 hours after taking this product. 2. Drugs containing metal ions such as calcium, magnesium, and iron can form insoluble complexes with this product, reducing the absorption of this product after oral administration. 3. When used in combination with the general anesthetic methoxyflurane, its nephrotoxicity can be enhanced. 4. When used in combination with strong diuretics such as furosemide, renal damage can be aggravated. 5. When used in combination with other hepatotoxic drugs (such as anti-tumor chemotherapy drugs), liver damage can be aggravated. 6. The lipid-lowering drugs colestyramine or colestipol can affect the absorption of this product, and must be taken separately for several hours. 7. This product can reduce the effect of contraceptives and increase the possibility of extramenstrual bleeding. 8. This product can inhibit the activity of plasma prothrombin, so patients receiving anticoagulant therapy need to adjust the dose of anticoagulants.

Keep away from light, sealed and stored in a dry place.

0.25g (250,000 units)

24 months

Jiangxi Aishite Pharmaceutical Co., Ltd.

• Founded in:

  2021-04-07

• Address:

  1st Floor, Quality Inspection Building, Jimin Trustworthy Headquarters and New Drug Industrialization Base Project (Phase I), No. 3333, Yaohu North Avenue, Nanchang High-tech Industrial Development Zone, Nanchang City, Jiangxi Province

• Tax NO.:

  91360106MA3ABY5N49

• Registered Funds:

  30 million yuan

• Email:

  Log in to view